-
J-VISIONS Vol. 4 Now Online: Read English Articles on Japanese Corporate IR
-
Synapse Analytics Secures US$13m Led by Partech to Drive AI-Powered Decisioning for Financial Institutions
-
In DR Congo streets, ex-hoods get tough on litter -- and locals
-
Bougainville leader says violence won't stop Panguna mine reopening
-
Noosha Aubel sorumluluk dersi veriyor, Potsdam’ın bozuk yolları yönetim zaafını ele veriyor
-
नूशा आउबेल देती हैं जिम्मेदारी का पाठ, पॉट्सडैम की बदहाल सड़कें खोलती हैं नेतृत्व की पोल
-
نوشا آوبل دم از مسئولیت میزند؛ خرابی خیابانهای پوتسدام گواه ضعف مدیریت اوست
-
Νούσα Άουμπελ: Μιλά για ευθύνη, μα οι άθλιοι δρόμοι του Πότσνταμ εκθέτουν τη διοίκησή της
-
ヌーシャ・アウベル、責任を説くもポツダムの道路の惨状が指導力不足を露呈
-
누샤 아우벨, 책임 외치지만 포츠담의 망가진 도로는 리더십 부실 드러내
-
努莎・奧貝爾大談責任,波茨坦道路破敗卻暴露其領導不力
-
نوشا أوبل تنادي بالمسؤولية، لكن طرق بوتسدام المتهالكة تكشف قصور قيادتها
-
Нуша Аубель проповідує відповідальність, а розбиті дороги Потсдама викривають провали керівництва
-
Нуша Аубель учит ответственности, но разбитые дороги Потсдама выдают провалы управления
-
Noosha Aubel poucza o odpowiedzialności, a fatalny stan dróg Poczdamu obnaża słabość jej rządów
-
Noosha Aubel calls for accountability in Potsdam; a road disaster highlights leadership shortcomings
-
Surfer hospitalised after shark attack in Western Australia
-
India cricketers refuse Asia Cup trophy from top Pakistan official
-
South Korea says 'serious shortage' of rooms with Asian Games days away
-
Japan's Okinawa ousts anti-US base governor
-
Table tennis siblings with China-born parents vow to usher in 'Japan's era'
-
Tech firms hit by AI slowdown call with Fed expected to hike rates
-
Bougainville leader says violence won't stop Panguna mine re-opening
-
US hosts G20 'energy abundance' talks amid Iran war shock
-
South Korea aims to save seniors lost in digital age
-
Migrant workers flock to Indian Kashmir despite militant threats
-
Russia's Stalin-admiring provincial leader waging an ultra-conservative crusade
-
Incubator shortages, premature births strain Gaza's hospitals
-
Marcelo Gallardo appointed as new Ecuador head coach
-
Canada's Carney seeks closer Europe ties to counter hostile US
-
'Widow's Bay' and 'The Pitt' tipped for success at Emmy Awards
-
Polls open in Philippine Muslim enclave after deadly shooting
-
For club and comfort: Rodman makes it to Shelton's US Open final
-
DC's Kennedy Center faces bankruptcy, closure: media
-
Houthis say Saudi Arabia launched over 50 strikes against them in 24 hours
-
Shelton hungry for more Grand Slam chances after US Open disappointment
-
'Fed up': Thousands march against Sinaloa Cartel violence
-
Bills edge Texans while Bears beat Panthers in NFL record-setting opener
-
The Art of Meal Prepping for a Stress-Free Week
-
AAHOA Officially Launches New Folio-Powered Marketplace to Simplify Purchasing for Members
-
Guardian Metal Resources PLC Announces Drilling Results Support Potential Resource Growth
-
Caledonia Mining Corporation Plc: Capital Markets Day Update
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - September 14
-
Controversial Zverev: from tennis nearly-man to multiple Grand Slam winner
-
Zverev holds off Shelton to win US Open title
-
Swedish left-wing cheers far-right decline amid tight election race
-
Torres fires PSG to first win of Ligue 1 season
-
Yamal double helps Barca beat Levante, Atletico triumph
-
Toulouse back on track after hammering Bordeaux
-
Sassuolo stun Juve, Lobotka eases pressure on Allegri with Napoli winner
Twitter prank spurs unexpected scrutiny of insulin prices
A Twitter imposter cost a US pharmaceutical giant billions of dollars, but the viral prank triggered another unexpected crisis -- a new wave of scrutiny of the high cost of its insulin.
Authentic-looking fake accounts proliferated last week after Twitter rolled out a paid verification service, the latest in a string of chaotic developments since Elon Musk's blockbuster $44 billion buyout of the influential platform.
Among the victims was drugmaker Eli Lilly, whose stock price nosedived -- erasing billions in market capitalization -- after a parody account stamped with a verification tag purchased for $8 tweeted that insulin was being made available for free.
The company was forced to issue an apology for the "misleading message from a fake Lily account," but the disinformation stirred fresh attention to a long-festering debate about high insulin prices.
"What you should *actually* apologize for is price gouging life-saving insulin," tweeted Chicago-based human rights lawyer Qasim Rashid.
"People are dying because of your greed (and) cruelty. Apologize for that."
Gaining traction alongside such comments was a cartoon meme with a half-elephant, half-human character riling up people to be more upset about the price of insulin than the price of gas.
"Fake Eli Lilly might be offering something closer to truth than real Eli Lilly," Peter Maybarduk, from the nonprofit Public Citizen, told AFP.
"Parody is successful when it reveals embarrassing and widely understood truth."
- 'Abusive pricing' -
In recent decades, insulin prices have soared in the United States, costing more than eight times more than in 32 comparable high-income countries, according to a 2020 Rand Corporation study.
A survey released in October by the nonprofit T1International showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
On Monday, which marks World Diabetes Day, dozens of advocacy groups including Public Citizen sent a letter to Congress demanding a stop to what they called insulin price-gouging.
"There's no defense for Eli Lilly's abusive insulin pricing," said Maybarduk.
"It's long past time we provide access to insulin for all, and yes –- it should be free," he added.
The backlash against Eli Lilly showcased the real-life potential of online disinformation to trigger chaos and financial loss. The company's stock price has marginally recovered since last week's drop.
But in this rare instance, it brought to the fore a much-ignored public health issue.
- 'Panic' -
"The disinformation is not without ramification -- Eli Lilly's stock price dropped dramatically," Al Tompkins, a senior faculty member at the Poynter Institute, told AFP.
But exploiting Twitter's chaotic rollout of its paid verification policy, the prank managed to make "the insulin drug price conversation relevant to a lot of people."
On Friday, Twitter disabled sign-ups for the contentious feature known as Twitter Blue, with reports saying it had been temporarily disabled to help address impersonation issues -- but not before several brands took a hit.
Shares of other firms such as aerospace defence company Lockheed Martin also took a hit after being targeted by impersonators.
The prank sparked panic inside Eli Lilly, with officials scrambling to contact Twitter representatives to take it down, but the platform did not react for hours, the Washington Post reported on Monday.
By Friday, Eli Lilly executives ordered a halt to all ad campaigns on Twitter, a move that could potentially cost the platform millions of dollars.
That would mark another blow to Twitter, which laid off nearly half its workforce after Musk's takeover as it struggles to boost revenue.
Eli Lilly and Twitter did not respond to AFP's request for comment.
J.Gomez--AT